CRNX - Crinetics Pharmaceuticals Appoints Robert M. Cuddihy M.D. as Senior Vice President of Medical Affairs | Benzinga
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs.
"Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the pharmaceutical industry is an invaluable addition to our talented scientific leadership team," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we forge ahead on the development and potential commercialization of our investigational product candidates, paltusotine and atumelnant, as well as build upon our deep pipeline of discovery candidates, Dr. Cuddihy will provide crucial and well-rounded expertise to help us to continue to build our reputation amongst the medical community."
Dr. Cuddihy added, "I've seen first-hand the devastating toll endocrine disease can take on patients, and I am eager to support Crinetics on advancing its cutting-edge pipeline as we strive to improve the lives of patients together. The therapies currently in development have shown impressive results across multiple endocrine diseases with high unmet need, with true potential to alter the treatment landscape and offer new, innovative options."
Prior to joining Crinetics, Dr. Cuddihy served as section chief, endocrinology, diabetes and ...